帕唑帕尼一线治疗不适合化疗的晚期软组织肉瘤II期研究
该II期研究评估帕唑帕尼作为不适合化疗的晚期软组织肉瘤患者一线治疗的疗效与安全性。56例初治患者入组,16周临床获益率为39.29%(22/56),中位无进展生存期3.67个月,中位总生存期14.16个月,未观察到新的不良事件。结果表明帕唑帕尼一线治疗对此类患者具有获益。
要点
- 帕唑帕尼一线治疗不适合化疗的晚期软组织肉瘤16周临床获益率达39.29%。
- 中位无进展生存期3.67个月,中位总生存期14.16个月。
- 常见III-IV级不良事件为高血压和肝功能异常,无新发意外事件。
核心结论
- 帕唑帕尼一线治疗不适合细胞毒化疗的晚期软组织肉瘤患者具有临床获益。
研究设计与样本
- 单臂II期研究,入组56例≥18岁、初治且不适合化疗的不可切除或转移性软组织肉瘤患者。
- 帕唑帕尼从200mg每日两次滴定至目标800mg每日一次。
- 主要终点为16周临床获益率(CBR,含完全缓解、部分缓解和疾病稳定,按RECIST 1.1)。
主要发现
- 56例患者纳入意向性分析,中位无进展生存期为3.67(2.62-7.25)个月。
- 中位总生存期为14.16(95%CI:8.4-NR)个月。
- 16周临床获益率为39.29%(22/56)(CI:0.265-0.533,p=0.0007)。
- 未观察到新的或意外的不良事件;最常见I-II级事件为腹泻、恶心和乏力,最常见III-IV级事件为高血压和肝功能异常。
关键数值与推荐
- 样本量56例可评价患者,计算提供80%把握度检验假设CBR≥35%对比不利CBR≤20%。
- 若≥17例患者达到获益,则在名义5%α水平拒绝20%的零假设CBR。
临床怎么用
- 对于不适合细胞毒化疗的晚期软组织肉瘤初治患者,可考虑帕唑帕尼作为一线治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cytotoxic chemotherapy remains the standard of care first-line treatment for advanced and metastatic soft-tissue sarcomas (STSs). Certain patients may not be chemotherapy candidates based upon age or co-morbidities, leaving limited treatment options. Pazopanib is a multi-targeted tyrosine kinase inhibitor that is FDA-approved for metastatic STS after the first line. We proposed a phase II study evaluating pazopanib as a first-line agent in patients with advanced disease who are deemed not to be candidates for chemotherapy. METHODS: Eligible patients were at least 18 years old, not candidates for chemotherapyand were treatment naive. Pazopanib was titrated from 200 mg twice daily to a goal of 800 mg daily. The primary end point was the clinical benefit rate (CBR) (CBR = completed response + partial response + stable disease per Response Evaluation Criteria in Solid Tumours [RECIST 1.1]) at 16 weeks. The sample size of 56 evaluable patients was calculated to provide 80% power to test a hypothesised CBR of ≥35% against an unfavourable CBR of ≤20%. If ≥ 17 patients achieved benefit, the null CBR of 20% would be rejected at a nominal 5% alpha level. Secondary end points included progression-free survival (PFS), overall survival (OS), quality of life and serum biomarkers. FINDINGS: Fifty-six patients were enrolled from May 2015 to February 2019 and are included in the intention-to-treat analysis. Median PFS was 3.67 (2.62-7.25) months. Median OS was 14.16 (95% confidence interval [CI]: 8.4-NR) months, CBR = 39.29% (22/56) (CI = 0.265-0.533, p = 0.0007). No new or unexpected adverse events were seen. The most common grade I-II events were diarrhoea, nausea and fatigue. The most common grade III-IV events were hypertension and liver function test abnormalities. INTERPRETATION: These data suggest that there is a benefit to front-line pazopanib in patients with STS who are not candidates for cytotoxic chemotherapy.
引用
- Hirbe AC, Eulo V, Moon CI, et al. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy. Eur J Cancer. 2020. PMID: 32712457. doi:10.1016/j.ejca.2020.06.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。